Barclays raised the firm’s price target on Encompass Health (EHC) to $153 from $150 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health: Solid Q4 Beat, Confident 2026 Outlook, and Contained Policy Risks Create Attractive Buy-Rated Risk/Reward
- Closing Bell Movers: Amazon slammed 10% on earnings, dragging down futures
- Encompass Health posts strong Q4 results and upbeat outlook
- Encompass Health reports Q4 adjusted EPS $1.46, consensus $1.30
- Encompass Health sees FY26 adjusted EPS $5.81-$6.10, consensus $5.82